Department of Pediatrics and Child Health Nursing, School of Health Sciences, College of Medicine and Health Sciences, Bahir Dar University, P.O. Box 196, Bahir Dar, Ethiopia.
Department of Pediatrics and Child Health Nursing, School of Nursing, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
BMC Public Health. 2020 Jan 20;20(1):82. doi: 10.1186/s12889-020-8160-8.
The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal.
We accessed Ethiopian Universities' online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger's regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies.
The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6-20.1%). Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95% confidence interval: 6.9-13.6%), 5.6% (95% confidence interval: 2.9-8.3%), and 6.3% (95% confidence interval: 4.6-8.0%), respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3-2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2-2.4), and poor adherence to highly active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3-11.8) on HIV treatment failure were estimated.
Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention programs need to address the specified contributing factors of human immunodeficiency virus treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus treatment adherence.
It has been registered in the PROSPERO database with a registration number of CRD42018100254.
为了提供新的宏伟目标的依据，需要了解埃塞俄比亚艾滋病毒治疗失败的国家负担和相关因素。
我们访问了埃塞俄比亚大学的在线资源库、Google Scholar、PubMed、Web of Science 和 Scopus，以获取研究文章。我们使用 I 平方统计来观察异质性。使用 Egger 回归检验检查发表偏倚。使用 DerSimonian-Laird 随机效应模型估计合并患病率。我们使用敏感性分析来检查纳入研究中是否存在异常值结果。
总体艾滋病毒治疗失败率为 15.9%（95%置信区间：11.6-20.1%）。使用免疫学、病毒学和临床定义，艾滋病毒治疗失败率分别为 10.2%（95%置信区间：6.9-13.6%）、5.6%（95%置信区间：2.9-8.3%）和 6.3%（95%置信区间：4.6-8.0%）。世界卫生组织临床分期 III/IV（调整后的优势比=1.9；95%置信区间：1.3-2.6）、机会性感染（调整后的优势比=1.8；95%置信区间：1.2-2.4）和抗逆转录病毒治疗依从性差（调整后的优势比=8.1；95%置信区间：4.3-11.8）对艾滋病毒治疗失败的综合影响进行了估计。
在埃塞俄比亚，艾滋病毒治疗失败率很高。处于晚期临床阶段、存在机会性感染和抗逆转录病毒治疗依从性差是艾滋病毒治疗失败的促成因素。艾滋病毒干预计划需要解决艾滋病毒治疗失败的特定促成因素。需要采取行为干预措施防止治疗中断，以维持艾滋病毒治疗的依从性。
该方案已在 PROSPERO 数据库中注册，注册号为 CRD42018100254。
